AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$AMGN

Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs

Amgen reported an 8% rise in third-quarter sales, driven by Repatha, Imdelltra, and Uplizna. Adjusted earnings per share increased 14% to $6.45, surpassing estimates. Revenue reached $10.4 billion, exceeding expectations. Amgen raised its full-year outlook, projecting adjusted earnings of $22.90 to $23.70 per share on revenue of $38.9 billion to $39.7 billion. Key drugs like Repatha and Evenity saw significant sales growth, while Prolia declined due to competition.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The beat reinforces Amgen's growth narrative, but upcoming trial results and regulatory risks remain key.

02

Market read

Amgen's earnings and guidance lift biotech sentiment and may boost related stocks.

03

What to watch

Potential competition for Repatha and pending FDA scrutiny of Tavneos could limit upside.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Amgen's Q3 earnings beat and guidance raise come amid a competitive landscape for cholesterol and bone drugs.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported Q3 sales up 8% and raised full-year adjusted earnings guidance to $22.90‑$23.70 per share, beating expectations.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

The company delivered better-than-expected revenue and EPS, and lifted its FY guidance, which typically triggers buying.

Market effects

Sector

Biotech and pharma sector may see broader optimism from Amgen's strong performance.

Regional

U.S. markets likely to open higher on Amgen's upbeat guidance.

Global

Amgen's results could influence global biotech sentiment, especially in Europe and Asia.

Counterpoint

What could challenge this read

Higher guidance may already be priced in; any miss on upcoming weight‑loss trial data could reverse gains.

Key entities

  • company
    Amgen

    U.S. biotech giant reporting earnings.

  • product
    Repatha

    Cholesterol drug driving sales growth.

Read at source← All news

StoryAmgen posts Q3 2026 earnings, lifts full‑year revenue and EPS outlook

Also covered by

6 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min